Straits Times Index
3,222.86 +13.68 (+0.43%) Nikkei
26,765.07 +160.23 (+0.60%) Hang Seng
20,687.66 +571.46 (+2.84%) FTSE 100
7,564.92 +42.17 (+0.56%) BTC-USD
29,000.93 -808.18 (-2.71%) CMC Crypto 200
628.95 -32.19 (-4.87%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 1.5600 |
| Open | 1.5500 |
| Bid | 1.5200 x 800 |
| Ask | 1.5600 x 3000 |
| Day's range | 1.5400 - 1.5900 |
| 52-week range | 1.4900 - 14.3800 |
| Volume | |
| Avg. volume | 723,869 |
| Market cap | 96.995M |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.25 |
- Business Wire
Precision BioSciences Appoints Juli Blanche as Chief People Officer
DURHAM, N.C., May 23, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences. Ms. Blanche is a human resources (HR) executive with over 25 years of strategic business partnership and enterprise leadership experience in the pharmaceutical an
- Business Wire
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
DURHAM, N.C., May 18, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus (HBV) has been published online in Molecular Therapy. Data from this study, "Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo," supp
- Business Wire
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
DURHAM, N.C., May 16, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical data will be presented this week on ARCUS genome editing including two oral presentations and two posters at the American Society of Gene & Cell Therapy (ASGCT), May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.
